LU91205I2 - Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco) - Google Patents

Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Info

Publication number
LU91205I2
LU91205I2 LU91205C LU91205C LU91205I2 LU 91205 I2 LU91205 I2 LU 91205I2 LU 91205 C LU91205 C LU 91205C LU 91205 C LU91205 C LU 91205C LU 91205 I2 LU91205 I2 LU 91205I2
Authority
LU
Luxembourg
Prior art keywords
alvesco
ciclesonide
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU91205C
Other languages
English (en)
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of LU91205I2 publication Critical patent/LU91205I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91205C 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco) LU91205I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57894290A 1990-09-07 1990-09-07

Publications (1)

Publication Number Publication Date
LU91205I2 true LU91205I2 (fr) 2006-05-30

Family

ID=24314964

Family Applications (2)

Application Number Title Priority Date Filing Date
LU88001A LU88001A1 (fr) 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires
LU91205C LU91205I2 (fr) 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU88001A LU88001A1 (fr) 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires

Country Status (18)

Country Link
US (1) US5482934A (fr)
JP (1) JP3292928B2 (fr)
KR (1) KR100193085B1 (fr)
AT (1) AT402930B (fr)
AU (1) AU649472B2 (fr)
BE (1) BE1005876A5 (fr)
BR (1) BR1100860A (fr)
CA (1) CA2050812C (fr)
CH (1) CH683343A5 (fr)
DE (2) DE4129535C2 (fr)
ES (1) ES2034893B1 (fr)
FR (1) FR2666585B1 (fr)
GB (1) GB2247680B (fr)
GR (1) GR1001529B (fr)
IT (1) IT1251376B (fr)
LU (2) LU88001A1 (fr)
NL (2) NL194917C (fr)
PT (1) PT98897B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
YU48707B (sh) 1990-03-02 1999-07-28 Glaxo Group Limited Aparat za inhaliranje - inhalator
ATE172739T1 (de) * 1993-04-02 1998-11-15 Byk Gulden Lomberg Chem Fab Neue prednisolonderivate
DK0749438T3 (da) * 1994-03-09 2001-04-02 Byk Gulden Lomberg Chem Fab Hidtil ukendte silylforbindelser og deres anvendelse
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
DE10055820C1 (de) * 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
EA006231B1 (ru) * 2000-11-10 2005-10-27 Алтана Фарма Аг Способ получения 16,17-[(циклогексилметилен)бис(окси)]-11,21-дигидроксипрегна-1,4-диен-3,20-диона или его 21-изобутирата транскетализацией
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PL373433A1 (en) * 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
WO2004033478A2 (fr) * 2002-10-08 2004-04-22 Sepracor Inc. Formes modifiees par l'acide gras des glucocorticoides
PT1572217E (pt) 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
CN100404545C (zh) * 2003-03-27 2008-07-23 尼科梅德有限责任公司 具有规定粒径的结晶环缩松的制备方法
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (fr) 2003-06-13 2006-03-22 ALTANA Pharma AG Combination de formoterol et ciclesonide
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
CA2538202C (fr) * 2003-09-15 2013-01-15 Altana Pharma Ag Utilisation de ciclesonide dans le traitement de maladies intestinales inflammatoires
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
CN100338089C (zh) * 2004-08-12 2007-09-19 重庆医药工业研究院有限责任公司 一种哮喘病治疗药物环索奈德的新的制备方法
EP1796679A1 (fr) * 2004-09-10 2007-06-20 Altana Pharma AG Combinaison de ciclesonide et d'inhibiteur de syk et procedes d'utilisation
CN100345864C (zh) * 2004-10-29 2007-10-31 天津药业研究院有限公司 一种治疗呼吸道疾病的甾体药物的制备方法及其中间体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
RU2008100237A (ru) * 2005-06-14 2009-07-20 Джилид Сайэнс, Инк. (US) ОБЩИЕ ПРОЛЕКАРСТВЕННЫЕ ФОРМЫ СТЕРОИДОВ И β-АГОНИСТОВ (ВАРИАНТЫ), ВКЛЮЧАЮЩИЙ ИХ АЭРОЗОЛЬНЫЙ СОСТАВ (ВАРИАНТЫ) И СПОСОБ ПРЕДОТВРАЩЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ЛЕГОЧНЫХ ВОСПАЛЕНИЙ И/ИЛИ БРОНХОСТЕНОЗА С ИХ ПОМОЩЬЮ
CN1325508C (zh) * 2005-06-21 2007-07-11 浙江仙琚制药股份有限公司 一锅法制备泼尼松龙衍生物
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
CN101300265A (zh) * 2005-09-02 2008-11-05 尼科克斯公司 糖皮质激素硝酰氧基衍生物
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2626628A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
WO2007045979A1 (fr) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
US20070135398A1 (en) * 2005-11-02 2007-06-14 Pierluigi Rossetto Process for the preparation of ciclesonide
EP1904514A2 (fr) * 2006-02-08 2008-04-02 Sicor, Inc. Formes cristallines de ciclesonide
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008015696A2 (fr) * 2006-05-23 2008-02-07 Cadila Healthcare Limited Procédé pour préparer le ciclésonide
TW200821316A (en) 2006-07-19 2008-05-16 Astrazeneca Ab Novel compounds 243
BRPI0715231A2 (pt) 2006-08-22 2013-06-25 Ranbaxy Lab Ltd compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto
WO2008062450A2 (fr) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Polymorphes cristallins de ciclésonide
CA2663737A1 (fr) 2006-09-19 2008-03-27 Cipla Limited Methodes de preparation de ciclesonide et sa modification cristalline
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008075005A1 (fr) 2006-12-19 2008-06-26 Astrazeneca Ab Dérivés quinuclidinol utilisés en tant qu'antagonistes du récepteur muscarinique
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
PT2124944E (pt) * 2007-03-14 2012-05-17 Ranbaxy Lab Ltd Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
EP2022796A1 (fr) * 2007-08-07 2009-02-11 Nycomed GmbH Ciclésonide amorphe
US20090075959A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ciclesonide
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (fr) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
EP2262823B1 (fr) * 2008-03-13 2013-01-23 Farmabios S.p.A. Procédé pour la préparation de dérivés de prégnane
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
CN102908624A (zh) * 2008-05-13 2013-02-06 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
CN102105448B (zh) 2008-05-27 2013-11-13 阿斯利康(瑞典)有限公司 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
WO2010067102A1 (fr) 2008-12-09 2010-06-17 Astrazeneca Ab Dérivés de diazaspiro[5.5]undécane et composés associés utilisés comme antagonistes des récepteurs muscariniques et agonistes des récepteurs bêta adrénergiques dans le traitement des affections pulmonaires
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2407476B1 (fr) * 2009-03-09 2014-05-07 Mikasa Seiyaku Co,. Ltd. Composé stéroïde
EP2228368A1 (fr) 2009-03-12 2010-09-15 Almirall, S.A. Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
EP2482822B1 (fr) 2009-10-01 2018-08-01 Adare Pharmaceuticals, Inc. Compositions de corticostéroïdes administrées par voie orale
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011079232A1 (fr) * 2009-12-23 2011-06-30 Psivida Us, Inc. Dispositifs d'administration à libération prolongée
WO2011093814A2 (fr) 2010-01-29 2011-08-04 Mahmut Bilgic Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2011136752A1 (fr) 2010-04-26 2011-11-03 Mahmut Bilgic Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
CN102477064B (zh) * 2010-11-23 2014-06-11 天津金耀集团有限公司 一种制备环索奈德的16,17缩酮中间体
EP2744479A1 (fr) 2011-08-18 2014-06-25 Takeda GmbH Produit aérosol pharmaceutique pour l'administration par inhalation orale ou nasale
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
WO2013109212A1 (fr) 2012-01-16 2013-07-25 Mahmut Bilgic Formulations en poudre sèche comprenant de la ciclésonide
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation contenant du glucose anhydre
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
WO2016120891A1 (fr) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Nouveau procédé de préparation de stéroïdes de type glucocorticoïde
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106749493A (zh) * 2017-01-09 2017-05-31 河南利华制药有限公司 一种哈西奈德中间体的制备工艺
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
KR20250069711A (ko) * 2022-07-21 2025-05-19 파이어플라이 바이오, 인크. 글루코코르티코이드 수용체 작용제 및 이의 접합체
WO2025085662A1 (fr) 2023-10-17 2025-04-24 Vanderbilt University Composés pour une utilisation tocolytique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3079384A (en) * 1960-10-10 1963-02-26 Olin Mathieson C-ring substituted 6alpha-halo steroids and process for producing them
SE378109B (fr) * 1972-05-19 1975-08-18 Bofors Ab
SE378110B (fr) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US4272446A (en) * 1974-02-27 1981-06-09 Pierrel S.P.A. Steroids and process for preparing the same
CH608244A5 (en) * 1974-02-27 1978-12-29 Pierrel Spa Process for the preparation of steroids
GB1504294A (en) * 1974-03-05 1978-03-15 Palladino G 6 beta-fluoropregnane compounds
NL7412537A (nl) * 1974-05-17 1975-11-19 Lark Spa Werkwijze voor het bereiden van 16.17-cyclische acetalen en ketalen van 9-(alpha)-halogeensteroiden.
US4036831A (en) * 1975-10-28 1977-07-19 Steroid Development Company Establishment Trimethyl siloxane steroid intermediates
DE3012888A1 (de) * 1980-03-31 1981-10-08 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neue steroide und verfahren zu ihrer herstellung
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
DE3640709A1 (de) * 1986-11-28 1988-06-09 Schering Ag Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate

Also Published As

Publication number Publication date
GB2247680A (en) 1992-03-11
US5482934A (en) 1996-01-09
AU8368691A (en) 1992-03-12
JPH04257599A (ja) 1992-09-11
KR100193085B1 (ko) 1999-06-15
FR2666585A1 (fr) 1992-03-13
DE4129535C2 (de) 2001-03-15
IT1251376B (it) 1995-05-09
CA2050812A1 (fr) 1992-03-08
ITMI912296A0 (it) 1991-08-28
DE122005000030I2 (de) 2007-12-06
CH683343A5 (de) 1994-02-28
FR2666585B1 (fr) 1994-09-09
JP3292928B2 (ja) 2002-06-17
CA2050812C (fr) 2003-07-29
ES2034893A1 (es) 1993-04-01
GR1001529B (el) 1994-03-31
DE4129535A1 (de) 1992-03-12
AU649472B2 (en) 1994-05-26
BR1100860A (pt) 1999-08-31
ITMI912296A1 (it) 1993-02-28
DE122005000030I1 (de) 2005-10-06
PT98897A (pt) 1992-07-31
HK1005881A1 (en) 1999-01-29
NL9101472A (nl) 1992-04-01
ATA176991A (de) 1997-02-15
LU88001A1 (fr) 1992-06-01
NL194917C (nl) 2003-09-01
GR910100353A (en) 1992-09-11
BE1005876A5 (nl) 1994-02-22
PT98897B (pt) 2000-10-31
GB2247680B (en) 1994-06-01
GB9118967D0 (en) 1991-10-23
NL300196I2 (nl) 2005-10-03
NL300196I1 (nl) 2005-08-01
ES2034893B1 (es) 1994-01-01
KR920006365A (ko) 1992-04-27
AT402930B (de) 1997-09-25

Similar Documents

Publication Publication Date Title
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU90037I2 (fr) Konakion et ses dérivés pharmaceutiquement acceptables
LU91197I2 (fr) Azoxystrobin et folpel et leurs dérivés pharmaceutiquement acceptables (QUADRIS MAX).
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
FI923677A7 (fi) Foerfarande och anordning foer entydig kombinering av foer en bestaemd behandling avsedda laekemedel med en bestaemd patient
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
BR9101311A (pt) Fralda
FI935920A7 (fi) Oksatsolidiinijohdannaiset ja niiden farmaseuttisesti hyväksyttävät suolat
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
NL300136I2 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
FI915855L (fi) Matalaestrogeenisia oraalisia raskaudenehkäisyvalmisteita
DK0535034T3 (da) Farmaceutisk aktive benzoquinazolinforbindelser
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
LU88843I2 (fr) Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)
OA09840A (fr) dérivés de pipéridine, leur préparation et leur application en thérapeutique
FI930674L (fi) Terapeutiska aemnen